AstraZeneca will present 33 abstracts from across the respiratory disease portfolio at the 2015 European Respiratory Society (ERS) meeting in Amsterdam, Netherlands, 26-30 September
AstraZeneca today announced findings from a new post-hoc analysis of two Phase III trials, in which dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 5 and 10 mg/d demonstrated greater reductions on HbA1c and systolic blood pressure (SBP) in patients with type 2 diabetes
AstraZeneca tillkännagav i dag publiceringen av viktiga data om total överlevnad (overall survival OS) från FIRST*-studien, en randomiserad, öppen multicenterstudie i fas II där man jämför första linjens behandling med östrogenreceptorantagonisten Faslodex® (fulvestrant) 500 mg mot aromatashämmaren Arimidex® (anastrozol), hos postmenopausala kvinnor med ER-positiv bröstcancer i avancerat stadium.
11 September 2015
AstraZeneca today announced that 54abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, 14-18 September 2015.
The presentations will include data on a number of approved products for the treatment of type 2 diabetes, including Forxiga®
AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
AstraZeneca, Göteborgs universitet och Chalmers meddelar i dag att man ingått ett nytt samarbete kring en avancerad utrustning for masspektrometri som gör att man på ett bättre sätt kan studera hur molekyler interagerar på cellulär nivå.
Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer (WCLC) 2015, beginning this weekend in Denver, Colorado.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year..
AstraZeneca today announced positive topline results from RECAPTURE 1and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI (ceftazidime-avibactam), as a treatment for adult hospitalised patients with complicated Urinary Tract Infections (cUTI), including pyelonephritis.
Idag presenterades resultaten från den svenska SUPPORT studien som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt (sekundärprevention) med hjälp av en mobiltelefonapplikation (”app”).
AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an exclusive license to develop and commercialise FluMist® Quadrivalent in Japan.
En ny studie som presenteradesden 1 september under den Europeiska hjärtläkarkongressen i London (ESC) visar att ticagrelor jämfört med clopidogrel minskar risken för allvarliga blödningar i samband med kranskärlskirurgi.
AstraZeneca fortsätter att skärpa fokus på sina viktigaste terapiområden och ett samarbete med en expert inom dermatologi förväntas snabba på utvecklingen av brodalumab för patienter med psoriasis och tillgodose ett betydande ouppfyllt behandlingsbehov
Data som presenterades vid European Society of Cardiologys kongress 2015 betonar behovet av långsiktig sekundärprevention för att förhindra nya hjärt-kärlhändelser
Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations.
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial wil
AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As C
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates
AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.